The anti-HIV drug tenofovir (Viread, and in Atripla and Truvada) is an effective part of combination therapy for HIV.
Researchers reviewed data from databases in California, Maryland, Virginia and Washington, DC. All participants began taking HAART between January 2002 and January 2006. In total, the researchers focused their analysis on data from 964 HIV-positive people who were taking tenofovir and 683 people who were not.
Tenofovir can damage part of the kidney called the renal tubules. The damage causes proximal renal dysfunction, which can lead to reduced efficiency filtering the blood, the loss of key nutrients and other problems such as the following:
Researchers checked eGFR (estimated glomerular filtration rate) to get an idea of how the kidneys were working. They divided people into the following two groups:
Apart from their use (or not) of tenofovir, the two groups of people were broadly similar, with the following average profile:
A high proportion of people in both groups achieved a suppressed viral load as follows:
At one year:
At two years:
These differences between groups were statistically significant. However, it is important to bear in mind that several randomized clinical trials have found that tenofovir-containing regimens have potent anti-HIV activity. So this particular finding from the Kaiser analysis is puzzling and unexpected and should be read with caution.
Creatinine is a waste product that is removed from the blood by the kidneys. When these organs are malfunctioning, creatinine levels in the blood can rise. Modest increases in blood levels of creatinine were more likely to occur in tenofovir users. But it is important to note that large increases in creatinine were not confined to tenofovir users. Indeed, people who had large increases in creatinine tended to have the following features:
Significantly more people using tenofovir developed proximal tubular dysfunction (8%) compared to people not taking tenofovir (4%). Furthermore, there was an increase in this problem over time, with the risk of proximal tubular dysfunction increasing among tenofovir users as follows:
Among people who developed proximal tubular dysfunction, 21% stopped taking tenofovir.
The findings from this Kaiser study are interesting but several points need to be taken into account when considering the results, including these:
It is not clear why in the present Kaiser analysis tenofovir was associated with more problems than reported in other trials. It might be that the Kaiser team was unable to account for potential confounding data such as the use of other drugs, which could increase the risk of kidney damage. Such drugs can include the following prescription and non-prescription medications:
For a more detailed list of drugs with the potential to cause kidney toxicity, please see CATIE's in-depth Fact Sheet on tenofovir.